LRRK2-IN-7 No Further a Mystery
All enrolled sufferers who been given no less than 1 dose of zosuquidar or placebo during induction had been monitored for that event of adverse functions (439 people, 219 on zosuquidar and 210 on placebo). The commonest adverse occasions have been relevant to the duration of extended and substantial myelosuppression as is anticipated with inductio